Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
The Food and Drug Administration (FDA) is amending its regulations regarding changes to an approved new drug application (NDA), biologics license application (BLA), or medical device premarket approval application (PMA). This final rule provides that a supplemental application submitted under certain FDA regulations is appropriate to amend the labeling for an approved product to reflect newly acquired information and to add or strengthen a contraindication, warning, precaution, or adverse reaction if there is sufficient evidence of a causal association with the drug, biologic, or device, as defined in other FDA regulations and guidance documents.
D001688:Biological Products; D018795:Device Approval / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D004864:Equipment and Supplies; D006801:Humans; D017387:Investigational New Drug Application / Q000331:legislation & jurisprudence*; D007883:Legislation, Medical; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products